TScan Therapeutics, Inc. TCRX
0.34
(0.01)
(2.86%)
as of 25 Sep
- Market cap
- $23.7M
- P/E
- 0.0×
Follow TCRX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
28.05 | 12.57 | 14.36 | 17.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.28) | (4.06) | (5.40) | (4.62) | |
P/B ratio |
1.64 | 1.05 | 1.35 | 1.85 | |
Price to Tangible BV |
1.64 | 1.05 | 1.35 | 1.85 | |
EV/Sales |
11.23 | 1.96 | 5.05 | 8.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.72) | (0.15) | (0.38) | (0.52) | |
EV/FCF |
(0.70) | (0.14) | (0.37) | (0.51) | |
Quick Ratio |
6.32 | 8.15 | 6.41 | 3.23 | |
Current Ratio |
6.44 | 8.41 | 6.65 | 3.37 | |
Net Debt/EBITDA |
4.19 | 5.18 | 3.35 | 2.26 | |
Debt/Assets |
12.36% | 14.22% | 16.17% | 19.12% | |
Debt/Equity |
0.23 | 0.26 | 0.34 | 0.47 | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
0.91 | 1.39 | 0.85 | 0.91 | |
Capex/Depreciation |
(1.86) | (0.24) | (0.10) | (0.67) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,262.01% | 780.64% | 2,230.55% | 2,226.64% | |
Selling, General and Administrative Expense of Revenue |
313.58% | 248.77% | 836.76% | 774.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
119.91% | 78.22% | 251.02% | 224.26% | |
Graham Net Nets |
0.30 | 0.40 | 0.21 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(61.54%) | (100.00%) | (95.05%) | (92.86%) | |
Free Cash Flow Yield |
(57.49%) | (107.67%) | (95.23%) | (92.98%) | |
Revenue per Share |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.25) | (0.25) | (0.19) | (0.21) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.25) | (0.19) | (0.22) | |
Cash per Share |
1.42 | 1.17 | 0.99 | 0.77 | |
Shareholders Equity per Share |
1.11 | 0.95 | 0.75 | 0.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.11 | 0.95 | 0.75 | 0.53 | |
Free Cash Flow |
(33.89) | (32.17) | (24.35) | (28.00) | |
Working Capital |
158.96 | 138.51 | 112.80 | 73.44 | |
Capital Expenditures |
(1.42) | (0.17) | (0.07) | (0.46) | |
Net Current Asset Value |
69.96 | 51.54 | 27.70 | 1.97 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.57 | 0.07 | 0.07 | 0.44 | |
Net Profit Margin |
(1,422.14%) | (895.09%) | (2,919.14%) | (2,888.58%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.00 | 2.76 | 3.63 | 3.83 | |
Average Assets |
305.13 | 299.95 | 267.35 | 235.01 | |
Average Common Equity |
186.55 | 182.05 | 153.56 | 122.87 |
Columns are period end dates